

or a pharmaceutically acceptable salt thereof.

7. A combination of claim 6 wherein the EGFR inhibitor is cetuximab.

8. A pharmaceutical combination according to claim 1 for use in the treatment of a proliferative disease in a subject in need thereof.

9. A pharmaceutical combination according to claim 1 for use in the preparation of a medicament for the treatment of a proliferative disease.

10. A pharmaceutical combination according to claim 9 wherein the proliferative disease is characterized by a B-Raf mutation.


11. A pharmaceutical combination according to claim 10 wherein the B-Raf mutation is a V600 mutation.

12. A pharmaceutical combination according to claim 11, wherein the proliferative disease is colorectal cancer.

13. Use of the combination according to claim 1 for the manufacture of a medicament for the treatment of a proliferative disease.

14. A method for treating a proliferative disease in a human patient wherein the proliferative disease is characterized by a B-Raf mutation, comprising the simultaneous, separate or sequential administration of a therapeutically effective amount of

(a) a B-Raf inhibitor of the formula




or a pharmaceutically acceptable salt thereof,

(b) an EGFR inhibitor, and, optionally,

(c) a PI3K-α inhibitor.

15. A method according to claim 14 wherein the B-Raf mutation is a V600 mutation.

16. A method according to claim 15, wherein the proliferative disease is colorectal cancer.



or a pharmaceutically acceptable salt thereof.

7. A combination of claim 6 wherein the EGFR inhibitor is cetuximab.

8. A pharmaceutical combination according to claim 1 for use in the treatment of a proliferative disease in a subject in need thereof.

9. A pharmaceutical combination according to claim 1 for use in the preparation of a medicament for the treatment of a proliferative disease.

10. A pharmaceutical combination according to claim 9 wherein the proliferative disease is characterized by a B-Raf mutation.


11. A pharmaceutical combination according to claim 10 wherein the B-Raf mutation is a V600 mutation.

12. A pharmaceutical combination according to claim 11, wherein the proliferative disease is colorectal cancer.

13. Use of the combination according to claim 1 for the manufacture of a medicament for the treatment of a proliferative disease.

14. Use of a simultaneous, separate or sequential administration of a therapeutically effective amount of

(a) a B-Raf inhibitor of the formula



or a pharmaceutically acceptable salt thereof,

(b) an EGFR inhibitor, and, optionally,

(c) a PI3K-α inhibitor,

in the manufacture of a medicament for treatment of a proliferative disease in a human patient wherein the proliferative disease is characterized by a B-Raf mutation.

15. The use according to claim 14 wherein the B-Raf mutation is a V600 mutation.

16. The use according to claim 15, wherein the proliferative disease is colorectal cancer.